Cargando…
Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
Medulloblastoma is the most common high-grade brain tumor in childhood. Medulloblastomas with c-myc amplification, classified as group 3, are the most aggressive among the four disease subtypes resulting in a 5-year overall survival of just above 50%. Despite current intensive therapy regimens, pati...
Autores principales: | Schwinn, Stefanie, Mokhtari, Zeinab, Thusek, Sina, Schneider, Theresa, Sirén, Anna-Leena, Tiemeyer, Nicola, Caruana, Ignazio, Miele, Evelina, Schlegel, Paul G., Beilhack, Andreas, Wölfl, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263612/ https://www.ncbi.nlm.nih.gov/pubmed/34234256 http://dx.doi.org/10.1038/s41598-021-93586-x |
Ejemplares similares
-
The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
por: Ehrhardt, Michael, et al.
Publicado: (2018) -
MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties
por: Dietl, Sebastian, et al.
Publicado: (2016) -
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015) -
MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022) -
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
por: Pagnuzzi-Boncompagni, Marina, et al.
Publicado: (2021)